Navigation Links
Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
Date:9/3/2009

t are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin ablation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:

    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329
    www.echotx.com


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
2. Selexis and NKT Therapeutics Enter Into Research Services Agreement
3. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
4. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
5. Nile Therapeutics Reports 2009 Second Quarter Financial Results
6. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
7. Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement
8. Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record
9. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
10. Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd.
11. Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Health structures explain nearly 20% of the non-adherence ... of a joint ESC-OECD study presented today at ... explained more than 80% of non-adherence. , Professor ... combines clinical data and health structure characteristics of ... the reasons some patients with heart failure do ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and home medical ... of its new office to be located in Greer, ... Suite D, Greer, SC 29651. This new location will ... convenient location in the Greenville area. , “This is ... hospitals and patients we serve, to ensure that we ...
(Date:9/2/2014)... 2014 “Harmonicas have been formally ... primarily to help people with COPD or asthma. ... developed systems,” says Dana Keller, PhD, co-inventor of ... goals are much the same – improved health ... of harmonica.” , The three approaches to harmonicas ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2
... ... Broadcasting Network recently released a story on Medi-Share, a Bible-based Healthcare ... Christian community by facilitating healthcare sharing for over 15 years. ... to share each other,s medical bills--almost 40,000 currently participate. Since ...
... success against E. coli , a common cause , ... urinary tract infections shows early promise in tests on mice, ... researchers have been trying to develop a vaccine to prevent ... and 14 percent of men at least once in their ...
... , COLLEGEVILLE, Pa. and SAN DIEGO, Sept. 18 ... WYE ) and Ambrx Inc. today announced the formation of ... candidates for three undisclosed targets in multiple therapeutic areas. ... applying its protein medicinal chemistry platform to proteins produced in ...
... , , RONKONKOMA, N.Y., Sept. 18 NBTY, Inc. ... global manufacturer and marketer of nutritional supplements, today announced that it will ... NBTY at two industry leading conferences. , , ... in New York on Tuesday, September 22, 2009 will be web cast ...
... ... "EXQ") today announced the successful completion of several key milestones in a custom-designed RNAi ... ... (NASDAQ OMX Copenhagen: "EXQ") today announced the successful completion of several key milestones ...
... ... technology to dramatically reduce appointment no-shows. , ... Scottsdale, AZ (PRWEB) September 18, 2009 -- In the span ... most important means of worldwide communication. Recent studies have consistently confirmed that mobile ...
Cached Medicine News:Health News:Medi-Share, a Bible-based Healthcare Option, Was Recently Featured on Christian Broadcasting Network 2Health News:Medi-Share, a Bible-based Healthcare Option, Was Recently Featured on Christian Broadcasting Network 3Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 2Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 3Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 4Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 2Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 3Health News:Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics 2Health News:Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics 3Health News:Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics 4Health News:Appointment-Plus Introduces Text-Ding™ Automated Text Message Appointment Reminders 2Health News:Appointment-Plus Introduces Text-Ding™ Automated Text Message Appointment Reminders 3
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... 29, 2014 Does your doctor know what you,re ... have recommended marijuana to the over 112,000 currently registered patients ... majority of the other roughly 20,300+ active physicians listed with ... about it – even though a poll in February 2014 ... they have tried it. "With marijuana legalization ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... Spinal Arthritis Receiving Monthly Golimumab Treatment Showed Marked Improvements in ... ... More than half of patients receiving,monthly subcutaneous (SC) injections of golimumab ... in the signs and,symptoms of active ankylosing spondylitis, according to Phase ...
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
Cached Medicine Technology:New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 2New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 3New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 4New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 5New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 6New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Quatroloc Revision Hip System...
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: